Array BioPharma

Array BioPharma
Company typeSubsidiary of Pfizer
IndustryOncology
Medication
Founded1998; 26 years ago (1998)
FounderDrs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou
Headquarters
Boulder, Colorado
,
Revenue$173.8 million (2018)
ParentPfizer
Websitewww.arraybiopharma.com

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]

In November 2000, the company became a public company via an initial public offering.[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.[3]

Discovery of FDA Approved Small Molecules

  • MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
  • TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
  • BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
  • KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
  • KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
  • VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)

References

  1. ^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
  2. ^ "Array IPO up 17%". CNN. November 17, 2000.
  3. ^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.
Authority control databases Edit this at Wikidata
  • ISNI